Exome Asset Management’s NextCure NXTC Stock Holding History

Exome Asset Management’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-115,500	Closed	-$1.22M	–	64
2026 Q1	$1.22M	Sell	115,500 -49,500	-30%	-$605K	0.63%	49
2025 Q4	$2.34M	Buy	+165,000	New	+$1.71M	1.12%	36

Other funds holding NXTC

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Exome Asset Management's NXTC Position: Q2 2026 in Review

Exome Asset Management sold out of NextCure (NXTC) in Q2 2026, closing a stake of 115,500 shares — an estimated $1.22M sold.

Exome Asset Management first reported a position in NXTC in Q4 2025 and held it in 2 quarters. The position peaked at $2.34M in Q4 2025. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Exome Asset Management reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
Exome Asset Management sold 115,500 NextCure shares in Q2 2026, an estimated $1.22M.
Exome Asset Management first reported a position in NextCure in Q4 2025 and held it in 2 quarters.
Exome Asset Management's NextCure position peaked at $2.34M in Q4 2025.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Exome Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.